Abstract

Expanding market access for new drug indications in emerging pharmaceutical markets presents a multifaceted challenge that spans regulatory, economic, and health system dimensions. These markets—characterized by diverse health policies, limited healthcare budgets, and heterogeneous regulatory environments—require tailored strategies to ensure timely and equitable access to therapeutic innovations. This proposes a Market Access Optimization Model designed to facilitate the strategic introduction of new drug indications within such complex and evolving landscapes. The model integrates key components of market access strategy, including regulatory alignment, value-based evidence generation, stakeholder engagement, and adaptable pricing frameworks. Using a data-driven and modular approach, it combines health technology assessment (HTA) principles with multi-criteria decision analysis (MCDA), epidemiological modeling, and budget impact simulations to optimize launch sequencing and market entry strategies. The model is designed to be context-sensitive, incorporating country-specific health infrastructure, disease burden, payer priorities, and socio-economic indicators to guide decision-making. Application scenarios across oncology, infectious diseases, and rare diseases in Latin America, Southeast Asia, and Sub-Saharan Africa demonstrate how the model supports pharmaceutical firms in prioritizing markets, customizing value propositions, and navigating reimbursement negotiations. Additionally, the framework provides policy makers and regulators with a structured approach to evaluate and accelerate the introduction of clinically relevant indications while safeguarding health system sustainability. By addressing key challenges—such as data fragmentation, pricing uncertainty, and regulatory heterogeneity—this model advances a pragmatic and scalable solution for improving access to medicines in low- and middle-income countries. This concludes with recommendations for cross-sector collaboration, digital innovation, and the use of real-world evidence to enhance adaptive decision-making. Ultimately, the Market Access Optimization Model serves as a strategic tool for aligning industry goals with public health objectives, fostering more inclusive and efficient access to innovative therapies in emerging pharmaceutical markets.